Skip to Content
Stock Analyst Update

Solid Performance Supports Sales Growth for Roche

The strong performance was partly due to pandemic headwinds in the second quarter of 2020 creating weaker comparisons.


We're maintaining our $59 fair value estimate for Roche (RHHBY) following strong second-quarter results, with top-line growth of 14%. The strong performance was partly due to pandemic headwinds in the second quarter of 2020 creating weaker comparisons and partly due to strong sales growth for Roche's diagnostics and innovative drugs. Core operating profit was up 4% in constant currency in the first half versus sales growth of 8%, due to a higher contribution from the lower-margin diagnostics arm as well as increased investment in pharma R&D. Roche continues to re-route its investment from sales and marketing and into R&D, with 19% growth in R&D expenses in the first half of 2021 for the pharma division, which we think bodes well for Roche's long-term competitive advantages. Roche confirmed its guidance for the full year of low- to mid-single-digit constant currency top-line growth and core earnings per share growth in line with sales growth. We think Roche's combination of branded drugs and diagnostics continues to support a wide moat.

There are several upcoming pipeline updates that could have a significant impact on our fair value estimate. First, Roche expects data in the third quarter for hematology drug Polivy in first-line DLBCL, which we think could allow total Polivy sales north of $2 billion (we model total sales of $1.7 billion by 2030). In 2022, we expect phase 3 data for Alzheimer's drug gantenerumab, which could allow Roche to compete with a cleaner data set than Biogen as well as more convenient subcutaneous dosing. We include a 20% probability of $3 billion in gantenerumab sales by 2030. Roche's SERD (breast cancer) and TIGIT (oncology) will also have pivotal data in 2022 and have potential for blockbuster sales. We expect Roche's newer approved therapies and solid pipeline will drive growth despite continued biosimilar pressure as well as potential new biosimilar launches for opthalmology drug Lucentis (2021) and immunology drug Actemra (2022). 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.